University of Washington cancer diagnostics spinout Bellwether Bio has been acquired by Guardant Health, which plans to integrate the former's expertise to advance its own pipeline.
Bellwether Bio, a US-based oncological diagnostics spinout of University of Washington, has been acquired by early cancer detection test company Guardant Health for an undisclosed sum.
Bellwether Bio is developing a cancer diagnostics approach that is intended to catch the disease earlier and more accurately than tests available to clinicians at present.
Bellwether’s approach focuses on searching for epigenetic changes associated with circulating cell-free DNA, small fragments that have splintered from cellular tissues such as tumours to drift…
